Pneumocystis jirovecii pneumonia in systemic rheumatic diseases: risk assessment and prophylaxis with emphasis on reduced-dose sulfamethoxazole/trimethoprim [0.03%]
系统性风湿病中卡氏肺孢子虫肺炎的风险评估及预防：小剂量磺胺甲恶唑/三甲氧苄氨嘧啶的使用分析
Shin-Ichiro Ohmura
Shin-Ichiro Ohmura
Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in patients with systemic rheumatic disease (SRD). Although less common than in HIV infection, PCP in patients with SRD worsens rapidly and is associated with high ...
Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance [0.03%]
小细胞肺癌的新兴疗法及转化研究进展：克服耐药性问题
Yuya Nishii,Yoh Yamaguchi,Tatsuya Yoshida
Yuya Nishii
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by rapid proliferation, early metastasis, and poor prognosis. Although initially sensitive to chemotherapy and radiotherapy, most patients relapse rapidl...
Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan [0.03%]
日本单中心队列研究中KRAS G12C突变型晚期非小细胞肺癌的临床转归路径分析
Yuta Okazaki,Hiroshige Yoshioka,Tatsuki Ikoma et al.
Yuta Okazaki et al.
Background: KRAS gene mutations occur in approximately 32% of lung adenocarcinomas in Western countries and 9.7% in Japan, with G12C being the most common. KRAS-mutated non-small cell lung cancer (NSCLC) typically has a p...
2,5-Dimethylcelecoxib inhibits lung fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis [0.03%]
2,5-二甲基塞来昔布抑制博莱霉素诱导的小鼠肺纤维化模型中的肺纤维化作用
Toshiki Morimoto,Shin Ishikane,Masaki Arioka et al.
Toshiki Morimoto et al.
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, incurable chronic lung disease characterized by irreversible fibrotic destruction. Current anti-fibrotic therapies are limited by adverse effects and high ...
Insulin-like growth factor 1 by lung fibroblasts from patients with idiopathic pulmonary fibrosis contributes to the development of fibrosis [0.03%]
特发性肺纤维化患者来源的成纤维细胞产生的胰岛素样生长因子1促纤维化作用的研究
Tomoko Kasamatsu-Nishimura,Masahiro Kitabatake,Noriko Ouji-Sageshima et al.
Tomoko Kasamatsu-Nishimura et al.
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial pneumonia with a poor prognosis. IPF is mainly caused by the excessive synthesis and accumulation of the extracellular matrix ...
Impact of erythromycin discontinuation owing to supply disruption on exacerbations in non-cystic fibrosis bronchiectasis: A retrospective cohort study [0.03%]
一项关于由于供应链中断而停止使用红霉素对非囊性纤维化支气管扩张症恶化的回顾性队列研究的影响
Takeshi Matsumoto,Hiroki Suga,Yuichi Kajiwara et al.
Takeshi Matsumoto et al.
Background: Long-term macrolide therapy reduces exacerbations in bronchiectasis; however, evidence regarding the outcomes after treatment discontinuation is limited. This study aimed to evaluate the effect of erythromycin...
Intravascular lymphoma mimicking hypersensitivity pneumonitis: A case report [0.03%]
类似过敏性肺炎的血管内淋巴瘤一例报告
Takuya Ozawa,Satoshi Okamori,Tomoya Uchida et al.
Takuya Ozawa et al.
Intravascular large B-cell lymphoma (IVLBCL) is a rare and often fatal malignancy that presents with non-specific pulmonary symptoms and abnormal imaging findings. We report a unique case of IVLBCL in a 73-year-old man who initially present...
Diagnostic and decision-making disparities in precision oncology in thoracic malignancies with interstitial pneumonia: A real-world cohort study [0.03%]
基于真实世界队列的胸部恶性肿瘤伴间质性肺炎精准肿瘤学诊断和决策差异的研究
Yutaro Kimura,Naozumi Hashimoto,Toshikazu Watanabe et al.
Yutaro Kimura et al.
Background: Patients with thoracic malignancy and interstitial pneumonia (IP) are often excluded from clinical trials, consequently lacking quantitative evidence of poorer prognosis and lower programmed death-ligand 1 (PD...
Short- and long-term outcomes of anti-thymocyte globulin-based regimen for acute antibody-mediated rejection after lung transplantation [0.03%]
抗胸肌球蛋白抗体治疗肺移植后急性和慢性抗体介导的排斥反应的短期和长期效果
Kentaroh Miyoshi,Shinji Otani,Seiichiro Sugimoto et al.
Kentaroh Miyoshi et al.
Background: Antibody-mediated rejection (AMR) remains a major barrier to successful lung transplantation (LTx). Despite advances in donor-specific alloantibody (DSA) detection, effective treatments are limited, with curre...